New iminodiacetate-thiosemicarbazone hybrids and their copper(II) complexes are potential ribonucleotide reductase R2 inhibitors with high antiproliferative activity

Mirela F. Zaltariov, Marta Hammerstad, Homayon J. Arabshahi, Katarina Jovanović, Klaus W. Richter, Maria Cazacu, Sergiu Shova, Mihaela Balan, Niels H. Andersen, Siniša Radulović, Jóhannes Reynisson, K. Kristoffer Andersson, Vladimir B. Arion

1 Institute of Inorganic Chemistry of the University of Vienna, Währinger Strasse 42, 1090 Vienna, Austria

2 “Petru Poni” Institute of Macromolecular Chemistry, Aleea G. Ghica Voda 41A, 700487, Iasi, Romania

3 Section for Biochemistry and Molecular Biology, Department of Biosciences, University of Oslo, P.O. Box 1066, Blindern, NO-0316 Oslo, Norway

4 School of Chemical Sciences, University of Auckland, New Zealand

5 Institute for Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia

6 Department of Chemistry, University of Oslo, P.O. Box 1033, Blindern, NO-0315 Oslo, Norway

7 Institute of Inorganic Chemistry – Functional Materials, Althanstrasse 14, 1090 Vienna, Austria
Abstract. As ribonucleotide reductase (RNR) plays a crucial role in nucleic acid metabolism, it is an important target for anticancer therapy. The thiosemicarbazone Triapine is an efficient R2-inhibitor, which has entered about 20 clinical trials. Thiosemicarbazones are supposed to exert their biological effects through effectively binding transition metal ions. In this study, six iminodiacetate-thiosemicarbazones able to form transition metal complexes, as well as six dicopper(II) complexes were synthesized and fully characterized by analytical, spectroscopic techniques (IR; UV–vis, $^1$H and $^{13}$C NMR), ESI mass spectrometry and X-ray diffraction. The antiproliferative effects were examined in several human cancer and one noncancerous cell lines. Several of the compounds showed high cytotoxicity and marked selectivity for cancer cells. Based on this, and on molecular docking calculations one lead dicopper(II) complex and one thiosemicarbazone were chosen for in vitro analysis as potential R2 inhibitors. Their interaction with R2 and effect on the Fe(III)$_2$-Y• cofactor were characterized by microscale thermophoresis, and two spectroscopic techniques, EPR and UV–vis spectroscopy. Our findings suggest that several of the synthesized proligands and copper(II) complexes are effective antiproliferative agents in several cancer cell lines, targeting RNR, which deserve further investigation as potential anticancer drugs.

Keywords: Copper(II) complexes, Iminodiacetate-thiosemicarbatone-hybrid, Anticancer, Ribonucleotide reductase, mouse R2 protein
Thiosemicarbazones are well-known for their versatile coordination chemistry, biological activity and theranostic applications.\textsuperscript{1,3} 3-Amino-2-pyridinecarboxaldehyde thiosemicarbazone, also referred to as Triapine, a very efficient inhibitor of ribonucleotide reductase (RNR),\textsuperscript{4} has entered a number of clinical trials\textsuperscript{5,6,7} and showed promising results in treatment of hematological diseases.\textsuperscript{8} However, low efficacy is detected in solid tumors,\textsuperscript{9} presumably because of rapid development of resistance,\textsuperscript{10} and, accompanied by marked side effects, e.g., methemoglobinemia.\textsuperscript{5,6,7} RNRs catalyze the conversion of ribonucleotides to their corresponding deoxyribonucleotides in all living organisms, providing the essential building blocks required for DNA replication and repair.\textsuperscript{11} The oxygen-dependent mammalian class Ia RNRs consist of two homodimeric subunits designated $\alpha_2$ (R1) and $\beta_2$ (R2). A radical-based catalytic mechanism is operative in the R1 subunit, where nucleotide reduction is initiated through the reversible one-electron oxidation of a conserved cysteine residue to a thyl radical. R2 houses a $\mu$-oxo-bridged diferric tyrosyl radical (Fe$^{\mathrm{III}}_2$-Y•) cofactor (Figure 1) essential for initiating thyl radical formation in R1.\textsuperscript{12} As RNR plays a crucial role in nucleic acid metabolism, it is target for several clinical drugs.\textsuperscript{13} Triapine has been shown to be a potent inhibitor of the R2 subunit of RNR, and, insights into the underlying mechanisms were reported.\textsuperscript{14} The understanding of, and the search for new compounds inactivating either the R1 or the R2 subunit of RNR is important for further optimization and development of new anticancer drugs.

![Figure 1. The RNR class Ia R2 subunit from mouse (PDBid:1W68).\textsuperscript{15} The radical-generating subunit is displayed as a monomer (left). The inset panel on the right shows the metal ion site, where the Fe ions are shown as orange spheres, and the coordinating amino acids and Tyr are represented as sticks and colored by atom type.](image)

Two thiosemicarbazones, (\textit{E})-N’-(6,7-dihydroquinolin-8(5H)-ylidene)-4-(pyridine-2-yl)piperazine-1-carbothiohydrazide (COTI-2), and di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC) (Chart 1) have entered phase I clinical trials in 2016,\textsuperscript{16,17} rekindling the interest in this class of
compounds and their metal complexes. COTI-2 is active against a large number of human tumor cell lines showing IC$_{50}$ values in the nanomolar concentration range and also in xenografts.$^{18}$ It was found to be superior to some first-line chemotherapy drugs such as cisplatin and BCNU$^{19,20}$ or targeted-therapy agents, such as cetuximab and erlotinib.$^{21}$ DpC, a member of the second generation of di-2-pyridylketone thiosemicarbazone (DpT) analogues, was identified as a lead drug candidate.$^{22}$ It has shown a number of advantages over another lead compound, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT), and, in particular higher antitumor activity in vivo, better tolerability when administered orally, lack of specific side-effects, and increased stability in blood plasma.$^{17,23}$

![Chart 1](image)

Chart 1. Line drawings of thiosemicarbazones in clinical trials and of (−)-monophyllidin.

Recently, we initiated synthesis of thiosemicarbazones originating from aldehydes closely related to (−)-monophyllidin (Chart 1),$^{24}$ a new alkaloid L-proline derivative from _Zanthoxylum monophillum_, which showed selective antibacterial activity against _Enterococcus faecalis_ 29212, with the aim of increasing aqueous solubility and extending structure–cytotoxicity relationship studies. Note that investigation of thiosemicarbazones as potential anticancer agents in the 1950s followed the studies which demonstrated their antiviral activity.$^{25,26}$ L- and D-proline 5-methyl-salicylaldehyde thiosemicarbazones along with their copper(II) complexes were prepared and compared for antiproliferative activity in vitro.$^{27}$ The synthesis was further extended by replacing the phenolic moiety by a pyridine functionality,$^{28}$ since it was known that _N_-heterocyclic thiosemicarbazones with potential NNS binding sites for transition metals have increased antiproliferative activity both in vitro and in vivo.$^{17}$ Highly water-soluble copper(II) L- and D-proline 2-pyridinecarboxaldehyde thiosemicarbazones were found to act as inhibitors of topoisomerase IIα and display antiproliferative activity in CH1 ovarian carcinoma cells.$^{29}$

Thiosemicarbazones exert their biological effects through the ability to effectively bind transition metal ions, in particular, iron(III).$^{30}$ Also, remarkable cell-dependent cytotoxicity of dicopper(II) and
dizinc(II) complexes with dinucleating ligands based on indolo[3,2-c]quinolines in A549 (nonsmall cell lung carcinoma), CH1 (ovarian carcinoma) and SW480 (colon adenocarcinoma) cell lines has been shown. Therefore, we decided to extend this last work on thiosemicarbazones by creating proligands able to form dimetal complexes, by including in their backbone a dialkyl-2,2'-iminodiacetate fragment (Chart 2). Incorporation of an iminodiacetate ligand into a dinuclear zinc(II) complex with phenanthroline was found favorable for inhibition of proliferation of hepatoma cell lines HepG2 and SMMC-7721, inducing cell cycle arrest in the G0/G1 phase. In addition, the complex showed low toxicity in mice (LD50 in ICR mice = 736 mg kg\(^{-1}\)). 31

![Chart 2](image-url)

**Chart 2.** Line drawing of dinucleating indoloquinoline EtOOCHLCOOEt.

Herein, to elucidate the structure–activity relationships (SARs), and to disclose their potential as R2 RNR inhibitors, we synthesized and characterized six proligands (Chart 3) by exploring the essential SAR derived from previous studies, in which the replacement of the terminal hydrogens by one or two alkyl group increased the cytotoxicity 23, 10 and six dicopper(II) complexes (Chart 4). One lead dicopper(II) complex and one thiosemicarbazone were found to be able to bind to the protein with low \(\mu M\) affinities, as well as having a noticeable effect on the R2 tyrosyl radical (\(Y^*\)) species as shown by using EPR and UV–vis spectroscopy. The utility of these methods along with rRaman spectroscopy in the studies of functional models of tyrosinase and galactose oxidase is well documented in the literature. 32, 12
Chart 3. Proligands studied in this work. All compounds have been investigated by X-ray crystallography.

\[
\begin{align*}
[H_2L^1]^- & \quad [H_2L^2]^- & \quad [H_2L^3]^- \\
[H_2L^4]^- & \quad [H_2L^5]^- & \quad [H_2L^6]^- \\
\end{align*}
\]

Chart 4. Copper(II) complexes studied in this work with line drawings for the ligands. All copper(II) complexes have been investigated by X-ray crystallography.
Results and Discussion

Syntheses. From the reaction of 3-(chloromethyl)-2-hydroxy-5-methylbenzaldehyde (species A in Scheme S1) with dimethyliminodiacetate hydrochloride in THF/DCM 1:1 in the presence of triethylamine, the aldehyde B (Scheme S1) was prepared in 83% yield. The latter was further reacted with a series of substituted 4N-thiosemicarbazides to give six new thiosemicarbazones, H₂L₁–H₂L₆ (Chart 3), with yields ranging from 76 to 93%. The identity and purity of the aldehyde B and proligands was confirmed by elemental analysis, ESI mass spectra, IR, UV–vis, ¹H and ¹³C NMR spectra (see Tables 1 and S1, Experimental, Figures S1–S25), as well as by X-ray crystallography (vide infra). The positive ESI mass spectra of all six proligands in methanol showed strong peaks attributed to [M + H]⁺ or [M + Na]⁺ or to both ions (see Experimental). Starting from CuCl₂·2H₂O and H₂L₁, and by using methanol as a solvent at 50–60 °C, complexes 1·2H₂O, 4, 5 and 6·0.5H₂O (Chart 4) were prepared with yields ranging from 19 to 63%. The reaction of Cu(OAc)₂·H₂O with H₂L₂ and H₂L₃ in methanol at room temperature afforded 2 and 3 (Chart 4) in 25 and 41% yield, respectively. The formation of dicopper(II) complexes 1–4 was confirmed by positive ion ESI mass spectra. X-ray crystallographic studies (vide infra) revealed that upon complex formation, four proligands underwent chemical transformations. Thus, in the presence of copper(II) acetate one of the two ester groups of proligands H₂L₂ and H₂L₃ hydrolyzed with formation of carboxylic function enabling its coordination to copper(II). Upon reaction of copper(II) chloride with H₂L₄, the –SiMe₃ group was replaced by –OMe originating from the solvent. Trimethylsilyl is generally known as a protecting group, which can then be easily cleaved by acid or base hydrolysis or by treating with fluoride ion. But, as compared to trimethylsilyl-oxygen, the trimethylsilyl-carbon bond is more hydrolytically stable surviving in a variety of synthetic transformations of the compounds, in which it is incorporated. However, the C–Si bond can be cleaved by electrophilic or nucleophilic agents. Both protic acids and Lewis acidic metal halides can be used as electrophiles.³⁴ It has been documented that this bond is also cleaved under mild conditions, e.g., in methanol in the presence of potassium carbonate³⁵ or potassium hydroxide,³⁶ silver nitrate in aqueous alcohol³⁷ and palladium salts.³⁸ In our case it would be assumed that copper(II) assists this replacement as a Lewis acidic metal center. In the presence of the same salt, an intramolecular cyclization via C–S coupling reaction between naphthyl carbon and thione group occurred in H₂L₅ with formation of a five-membered thiaza ring. The generated group is of great interest in bioactive systems.³⁹ Only tautomeric changes were noticed upon complex formation between CuCl₂ and H₂L₆. Nevertheless, we marked this modification by using an italic L for the ligand, as was also the case for the other four new ligands formed upon complex formation (see Chart 4). The IR spectra of the complexes showed
the blueshifted azomethine and carbonyl ester group vibrations as a result of coordination of Cu(II) ions by N and O donor atoms (Table 1 and Figures S26–S31).

Table 1. Assignment of the main characteristic bands in the IR spectra of the proligands and complexes 1–6.

<table>
<thead>
<tr>
<th>Assignment</th>
<th>Wavenumber (cm(^{-1}))</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>B</td>
</tr>
<tr>
<td>u(O–H)</td>
<td>3290</td>
</tr>
<tr>
<td>u(NH(_2))</td>
<td>-</td>
</tr>
<tr>
<td>u(N–H)</td>
<td>-</td>
</tr>
<tr>
<td>u(C–H)(_{\text{aromatic}})</td>
<td>3015</td>
</tr>
<tr>
<td>u(C–H)(_{\text{aliphatic}})</td>
<td>2945</td>
</tr>
<tr>
<td>u(C=O)(_{\text{ester}})</td>
<td>1740</td>
</tr>
<tr>
<td>u(C=O)(_{\text{aldehyde}})</td>
<td>1674</td>
</tr>
<tr>
<td>u(_{\text{as}})(COO(^{-}))</td>
<td>-</td>
</tr>
<tr>
<td>u(_{\text{s}})(COO(^{-}))</td>
<td>-</td>
</tr>
<tr>
<td>u(CH=N)</td>
<td>-</td>
</tr>
<tr>
<td>(u_{\text{thiazole ring}})</td>
<td>-</td>
</tr>
<tr>
<td>(u_{\text{thiazole I-IV}})</td>
<td>-</td>
</tr>
<tr>
<td>(u_{\text{thiazole I-IV}})</td>
<td>-</td>
</tr>
<tr>
<td>u(CH=CH(_3))</td>
<td>-</td>
</tr>
<tr>
<td>u(C=N)</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>-</td>
</tr>
<tr>
<td>u(N–N)</td>
<td>-</td>
</tr>
<tr>
<td>u(C–N)</td>
<td>1269</td>
</tr>
<tr>
<td>u(S–CH(_3))</td>
<td>-</td>
</tr>
<tr>
<td>u(O–CH(_3))</td>
<td>-</td>
</tr>
<tr>
<td>u(Si–CH(_3))</td>
<td>-</td>
</tr>
</tbody>
</table>

The electronic absorption spectra of complexes in methanol showed the presence of broad and intense bands attributed to LMCT transitions at 374, 376, 375, 380, 417, and 370 nm, and to d-d transitions with maxima at 660, 638, 638, 634, 696 and 658 nm for 1–6, respectively. All six complexes were found to crystallize from methanol with formation of X-ray diffraction quality
single crystals, which were investigated by X-ray crystallography (vide infra). In the case of 1 and 5, the identity of single crystals with bulk samples was verified by powder diffraction measurements through the comparison to the calculated from single crystal X-ray data diffractograms (see Figures S32 and S33).

**X-ray crystallography.** The results of X-ray diffraction studies of proligands $\text{H}_2\text{L}_1^{-\text{H}_2\text{L}_6}$ are shown in Figure 2, while those of complexes 1–6 in Figures 3 and 4. All six ligands act as binucleating accommodating two copper(II) ions. The ion Cu1 in complexes 1, 4 and 6 adopts distorted square-pyramidal coordination geometry with calculated $\tau$ descriptor\(^{40}\) of 0.30, 0.35 and 0.21, respectively, while in 5 the $\tau$ descriptor of 0.60 indicates a slow tendency towards a trigonal-bipiramidal environment around Cu1. The five coordination places surrounding Cu1 in 1 and 4 are occupied by ONS donor atoms, while in 5 and 6 by ONN donor atoms of the thiosemicarbazone moiety. In addition, in all four complexes, two chlorido ligands are bound to Cu1, one of which acts as bridging one to Cu2. The coordination environment of Cu2 is shown as four, five or six-coordinate with phenolato oxygen atom O1, iminodiacetate nitrogen N4 and two chloride ligands Cl2 and Cl3 in equatorial plane, with no or very weakly coordinated apical or axial iminodiacetate oxygen atoms (see Figure 3 (a-d)). However, taking into account the corresponding interatomic distances the coordination environment at Cu2(Cu2a) should be described as six-coordinate in all four cases with weak axial binding of iminodiacetate oxygen atoms (see legend to Figure 3).
Figure 2. ORTEP views of a) \( H_2L_1 \), b) \( H_2L_2 \), c) \( H_2L_3 \), d) \( H_2L_4 \), e) \( H_2L_5 \) and f) \( H_2L_6 \).
Figure 3. ORTEP views of a) 1, b) 4, c) 5 and d) 6. Selected bond lengths and bond angles in 1: Cu1–O1 1.984(3), Cu1–N1 1.990(4), Cu1–S1 2.2641(14), Cu1–Cl(1) 2.2652(12), Cu1–Cl(2) 2.6162(13), Cu2–O1 2.027(3), Cu2–N4 2.093(4), Cu2–Cl(2) 2.2853(13), Cu2–Cl(3) 2.2641(13), Cu2–O3 2.383(3), Cu2–O5 2.438(4) Å; O3–Cu2–O5 151.61(13), Cu1–Cu1–Cu2 110.76(16), Cu1–Cl(2)–Cu2 84.37(4)°; in 4: Cu1–O1 1.979(2), Cu1–N1 1.982(3), Cu1–S1 2.2862(10), Cu1–Cl(1) 2.2717(10), Cu1–Cl(2) 2.5684(10), Cu2–O1 2.016(2), Cu2–N4 2.099(3), Cu2–Cl(2) 2.2962(10), Cu2–Cl(3) 2.2324(10), Cu2–O3 2.468(3), Cu2–O5 2.556(3) Å; O3–Cu2–O5 148.65(9), Cu1–Cu1–Cu2 112.43(11), Cu1–Cl(2)–Cu2 85.92(3)°; in 5: Cu1–O1 1.937(4), Cu1–N1 2.024(4), Cu1–N3 2.029(4), Cu1–Cl(1) 2.2565(16), Cu1–Cl(2) 2.5667(15), Cu2–O1 2.012(3), Cu2–N4 2.079(4), Cu2–Cl(2) 2.2614(15), Cu2–Cl(3) 2.2451(15), Cu2–O3 2.390(4), Cu2–O4 2.555(4) Å; O3–Cu2–O5 149.26(14), Cu1–Cu1–Cu2 111.85(17), Cu1–Cl(2)–Cu2 85.06(5)°; in 6: Cula–O1a 1.955(3), Cula–N1a 1.999(3), Cula–N3a 1.957(3), Cula–Cl(1a) 2.6357(12), Cula–Cl(2a) 2.2367(10), Cu2a–O1a 2.013(3), Cu2a–N4a 2.088(3), Cu2a–Cl(1a) 2.2753(11), Cu2a–Cl(3a) 2.2692(11), Cu2a–O3a 2.363(3), Cu2a–O4a 2.512(3) Å; O3–Cu2–O5 148.95(12), Cula–O1a–Cu2a 114.62(13), Cula–Cl(1a)–Cu2a 85.37(4)°.
In complexes 2 and 3, ligands \((L^2)^3\) and \((L^3)^3\) and one bridging methoxido group provide square-planar environment around both Cu1 and Cu2. Further inspection of the crystal structures revealed formation of tetranuclear associates via centrosymmetric intermolecular contacts Cu2–S1 and Cu1–O6(methoxido) (see Figures S34 and S35), so that the coordination geometry should be described as square-pyramidal for both Cu1 and Cu2 (\(\tau\) descriptor 0.01 and 0.04 for 2 and 3, respectively).

**MTT assay.** Cytotoxic activity of the investigated copper(II) complexes 1–6 and cisplatin (CDDP) as standard cytotoxic agent was determined by the MTT assay after 48 h treatment of four tumor cell lines (HeLa, A549, K562, LS-174) and one normal cell line (MRC-5). The results are shown in Table 2. Mean IC50 values were calculated from two to three independent experiments and presented with their standard deviations.

Results of this assay indicate that most of the investigated complexes and the corresponding proligands exhibit moderate to strong cytotoxic activity towards all tested cell lines, comparable or even stronger than cisplatin.
Comparison of cytotoxic activity of the complexes with their corresponding proligands shows that complexation with copper(II) may have a different impact on the cytotoxicity properties of these types of compounds. For the $1 - H_2L^1$ and $5 - H_2L^5$ complex-proligand pairs, introducing a copper center into the organic ligand results in significant increase in cytotoxic activity in all investigated cell lines. The most prominent increase in cytotoxic activity is noted in the $5 - H_2L^5$ complex-proligand pair, with IC$_{50}$ values not reached in the examined range of concentrations for the proligand, and with IC$_{50}$ values of $14.4 \pm 1.0$, $14.9 \pm 0.1$ and $11.7 \pm 0.4$ μM on HeLa, A549 and LS-174 cell lines respectively, for $5$ (Table 2). Besides increased cytotoxicity, the absence of selectivity towards cancer cell lines should be taken into account for the two complexes $1$ and $5$.

**Table 2.** Results of MTT assay presented as IC$_{50}$ (μM) values obtained after 48 h incubation.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>3.7 ± 0.6</td>
<td>3.2 ± 0.1</td>
<td>4.3 ± 0.6</td>
<td>4.1 ± 0.3</td>
<td>5.7 ± 0.4</td>
<td>1.8</td>
</tr>
<tr>
<td>2</td>
<td>6.1 ± 0.4</td>
<td>3.8 ± 0.1</td>
<td>17.7 ± 1.0</td>
<td>12.6 ± 1.3</td>
<td>12.3 ± 1.4</td>
<td>3.2</td>
</tr>
<tr>
<td>3</td>
<td>21.0 ± 0.9</td>
<td>12.7 ± 1.3</td>
<td>95.5 ± 3.5</td>
<td>65.6 ± 2.0</td>
<td>&gt;100</td>
<td>&gt;7.9</td>
</tr>
<tr>
<td>4</td>
<td>5.5 ± 0.4</td>
<td>5.8 ± 0.4</td>
<td>13.1 ± 1.3</td>
<td>9.4 ± 0.1</td>
<td>11.0 ± 0.3</td>
<td>1.9</td>
</tr>
<tr>
<td>5</td>
<td>14.4 ± 1.0</td>
<td>16.1 ± 1.5</td>
<td>14.9 ± 0.0</td>
<td>11.7 ± 0.4</td>
<td>13.9 ± 0.1</td>
<td>0.9</td>
</tr>
<tr>
<td>6</td>
<td>6.0 ± 0.6</td>
<td>7.2 ± 0.7</td>
<td>9.3 ± 0.8</td>
<td>8.7 ± 0.1</td>
<td>13.0 ± 1.0</td>
<td>1.8</td>
</tr>
<tr>
<td>$H_2L^1$</td>
<td>31.1 ± 2.3</td>
<td>7.1 ± 0.5</td>
<td>45.5 ± 4.8</td>
<td>40.0 ± 2.8</td>
<td>&gt;100</td>
<td>&gt;14.1</td>
</tr>
<tr>
<td>$H_2L^2$</td>
<td>4.2 ± 0.3</td>
<td>4.8 ± 0.4</td>
<td>5.4 ± 0.0</td>
<td>4.7 ± 0.6</td>
<td>99.1 ± 0.4</td>
<td>20.7</td>
</tr>
<tr>
<td>$H_2L^3$</td>
<td>3.9 ± 0.2</td>
<td>6.1 ± 0.7</td>
<td>8.5 ± 0.3</td>
<td>4.7 ± 0.2</td>
<td>84.7 ± 3.6</td>
<td>13.9</td>
</tr>
<tr>
<td>$H_2L^4$</td>
<td>6.1 ± 0.7</td>
<td>5.9 ± 0.1</td>
<td>13.6 ± 1.5</td>
<td>14.5 ± 0.3</td>
<td>19.4 ± 1.2</td>
<td>3.3</td>
</tr>
<tr>
<td>$H_2L^5$</td>
<td>&gt;100</td>
<td>27.5 ± 1.2</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;3.6</td>
</tr>
<tr>
<td>$H_2L^6$</td>
<td>15.6 ± 2.8</td>
<td>5.1 ± 0.5</td>
<td>31.9 ± 1.8</td>
<td>16.2 ± 0.2</td>
<td>20.7 ± 1.2</td>
<td>4.1</td>
</tr>
<tr>
<td>CDDP</td>
<td>5.2 ± 0.3</td>
<td>18.6 ± 3.3</td>
<td>26.2 ± 5.4</td>
<td>22.4 ± 7.2</td>
<td>12.1 ± 0.9</td>
<td>0.7</td>
</tr>
</tbody>
</table>

The sign $>$ (in front of the maximum value of the concentration) indicates that IC$_{50}$ value is not reached in the examined range of concentrations. $^{a}$SI = Selectivity index; SI$_{1} = $ IC$_{50}$(MRC-5)/IC$_{50}$(K562).
For the $3 - \text{H}_2\text{L}^3$ complex-proligand pair, after binding of the copper(II) to the thiosemicarbazone ligand, a major drop in the cytotoxic activity occurs (Table 2). IC$_{50}$ values increase starting from twofold ($6.1 \pm 0.7$ vs $12.7 \pm 1.3$ μM for K562 cell line), to above tenfold ($8.5 \pm 0.3$ vs $95.5 \pm 3.5$ μM for A549 cell line, and $4.7 \pm 0.2$ vs $65.6 \pm 2.0$ μM for LS-174 cell line). Interestingly, exhibited proligand selectivity towards cancer cells decreases or disappears completely with the formation of $3$.

For the $2 - \text{H}_2\text{L}^2$, $6 - \text{H}_2\text{L}^6$, and $4 - \text{H}_2\text{L}^4$ complex-proligand pairs, introduction of the copper(II) center did not result in significant change in the cytotoxic activity. Proligand $\text{H}_2\text{L}^2$ exhibits great μM on HeLa, K562, A549 and LS-174 cell lines, respectively, vs $99.1 \pm 0.4$ μM on the MRC-5 cell line. With the formation of $2$, the selectivity towards cancer cells seen by the corresponding proligand decreases or disappears completely, in a similar way as in $3$. However, this complex together with its corresponding proligand show cytotoxic activity stronger than that of cisplatin in most of the examined cancer cell lines, which is promising for further investigations.

It is well-known, that methylation of thiosemicarbazones at sulfur atom changes their mode of coordination to the majority of transition metals. This can be a reason for the divergent effect of thiomethylation on antiproliferative activity of proligands and their dicopper(II) complexes, elucidated by comparison of the IC$_{50}$ values of $\text{H}_2\text{L}^1$ and $\text{H}_2\text{L}^6$, as well as of $1$ and $6$. Thiomethylated proligand $\text{H}_2\text{L}^6$ is more cytotoxic than nonmethylated proligand $\text{H}_2\text{L}^1$, while its copper(II) complex $6$ is less active against cancer cell lines than $1$.

Copper(II) complexes with hydroxyquinoline 2-carboxaldehyde thiosemicarbazones showed antiproliferative activity in lung adenocarcinoma cancer cells A549 with IC$_{50}$ values in submicromolar concentration range, which is by more than one order of magnitude higher than that of the corresponding metal-free thiosemicarbazones, associated with cell cycle arrest in the G$_2$/M phase. The complexes do not induce ROS accumulation in the cells and do not produce DNA damage. In contrast, chemically induced DNA cleavage presumably via singlet oxygen and hydroxyl radical generation was documented for copper(II) complex with quinoline-2-carboxaldehyde thiosemicarbazone. Copper(II) 2-hydroxybenzaldehyde thiosemicarbazonates were found to be significantly more cytotoxic in A549 cells than the corresponding metal-free thiosemicarbazones with IC$_{50}$ values from 0.95 to 2.19 μM compared to 4.4 to 95.5 μM for $1$–$6$. At the same time the metal-free thiosemicarbazones are markedly less active than iminodiacetate-
thiosemicarbazone hybrids $\text{H}_2\text{L}_2$, $\text{H}_2\text{L}_3$, $\text{H}_2\text{L}_4$ and $\text{H}_2\text{L}_6$ studied in this work.\textsuperscript{44} Flow cytometry showed a marked accumulation of the cells in S phase upon increasing the concentration of copper(II) complexes in human hepatoma BEL-7404 cells. The complexes induce apoptosis via the mitochondrial ROS generation. A similar mechanism of apoptosis was reported for copper(II) complexes with 2-pyridinecarboxaldehyde- and di(2-pyridyl)ketone thiosemicarbazones.\textsuperscript{45} Related copper(II) complexes with 2-benzoylpyridine thiosemicarbazones showed antiproliferative activities in submicromolar concentration range and were more cytotoxic than the thiosemicarbazones themselves.\textsuperscript{46} The underlying mechanism of antiproliferative activity of the copper(II) complexes is due to induced early apoptosis via ROS accumulation in the cells and DNA cleavage. Although some of the recently reported copper(II) complexes with thiosemicarbazones exhibit high antiproliferative activity in cancer cells, the reported data on selectivity for cancer cells are scarce.\textsuperscript{47}

For further investigations compounds were selected from the series of proligands and dicopper(II) complexes based on their selectivity to cancer cells (see Table 2).

**Cell cycle analysis.** Cell cycle analysis of K562 cells treated with copper(II) complexes and their corresponding proligands 2 – $\text{H}_2\text{L}_2$ and 3 – $\text{H}_2\text{L}_3$, as well as with cisplatin was performed by flow cytometry after staining with propidium iodide.\textsuperscript{48} Cells were continuously exposed to the investigated compounds and cisplatin for 24 and 48 h with concentrations corresponding to their IC\textsubscript{50} values as shown in Table 2.
After 24 h of continuous treatment with the investigated compounds, only mild increase in the sub-G1 and G1 populations of the K562 cells treated with $\text{H}_2\text{L}^3$ was noted, compared to the control population of cells. On the contrary, treatment with cisplatin, which was used as the positive control for this experiment, induced significant increase in the sub-G1 population of cells (Figure 5, upper chart).

After 48 h of continuous treatment there was an increase in the sub-G1 population of 2 treated cells, which may denote apoptotic and/or necrotic fraction of cells. Additionally, an S-phase arrest was also noticed, indicating possible binding of 2 to DNA of K562 cells. Further investigations regarding apoptotic potential of this complex was performed.

**Apoptotic assay.** Analysis of the apoptotic potential of 2 was investigated by flow cytometry dual staining of K562 cells with Annexin V-FITC and PI, method that enables detection of translocation of phosphatidylserine from the inner to the outer side of plasma membrane during apoptosis.

---

**Figure 5.** Effect of the investigated copper(II) complexes and cisplatin (CDDP) on cell cycle progression of K562 cells following 24 (upper chart) and 48 h (lower chart) incubation with concentrations of the investigated complexes corresponding to their IC$_{50}$s. Controls were untreated cells (incubated with nutrient medium only). The results are expressed as mean ± standard deviations of three independent experiments.
Results shown in Figure 6 indicate that after 48 h treatment with 2, no increase in the number of cells labeled with Annexin V-FITC (early apoptotic), nor cells labeled with both dyes Annexin V-FITC and PI (late apoptotic and necrotic cells) was found, as compared to the control. However, after treatment with an IC$_{50}$ concentration of complex 2, the number of dead cells increased slightly, as compared to the control population (from 2.93 to 3.95%). A notable increase in percentage of dead cells is achieved after treatment with 1.5 × IC$_{50}$ concentration of complex 2 (6.44% of dead cells). These results are in agreement with the results obtained from cell cycle analysis, where treatment with 2 induced an increase in the sub-G1 population of K562 cells (Figure 5). However, absence of early and late apoptotic populations of cells suggests that other mechanisms of cytotoxic activity are involved in the case of 2.

![Figure 6. Apoptosis induction by complex 2 and CDDP.](image)

Molecular docking of RNR inhibitors – H$_2$L$^2$ and complex 3. To explain the findings from cytotoxicity assays and estimate the likelihood of binding to mouse R2 RNR, docking studies of R2 (PDBid:1W68) with the active compounds H$_2$L$^2$ and 3 were conducted. The GoldScore (GS) scoring function was used to conduct the docking calculations, giving arbitrary numbers with higher values predicting better binding. Docking of copper(II) complex 3 resulted in a predicted pose across the binding pocket, the hydrophobic core was positioned deep in the pocket across several hydrophobic contacts (Figure 7). It gave a GS of 47 and predicted a single hydrogen bonding interaction with Ser264. Interestingly, its neighboring residue Ile263 is in close proximity to the Y• (Tyr177) and
may influence Y• stability (Figure 8). Docking of $H_2L^2$ (GS = 48) showed a slightly altered pose within the binding pocket (Figure 7) but was also predicted to have the hydrophobic core situated deep in the pocket, and shared the hydrogen bonding interaction to Ser264. Similar docking results of the active compounds suggest plausible binding to R2 RNR. However, a crystal structure would give more comprehensive information about the interaction of $H_2L^2$ and 3 with the R2 protein.

Figure 7. Binding site of RNR R2 (PDBid:1W68), showing the docked configuration of $H_2L^2$ (A) and of complex 3 (B). The protein surface is rendered, blue and red depict positive and negative charges, respectively.
Interaction with Ribonucleotide Reductase – Binding Affinity Measurements. Biomolecular interaction analysis gives fundamental insights into the molecular biology of the cell, but is also an important pharmacological tool. Microscale Thermophoresis (MST) allows for quantitative analysis of protein interactions in solution, and is sensitive to all types of binding-induced changes of molecular properties, such as size, charge, solvation shell or conformation. The technique is based on thermophoresis, the directed motion of molecules in temperature gradients. Initially, an infrared laser is used for heating of the samples, and the movement of molecules in the temperature gradient can be analyzed via protein intrinsic UV-fluorescence. The intrinsic protein fluorescence upon interaction with the proligands or metal complexes arises from the aromatic amino acids, with tryptophan (Trp) being the dominant intrinsic fluorophore. As a change in the fluorescence intensity was observed with increasing concentrations of both compounds, $H_2L^2$ and 3, the fluorescence quenching signal was used directly for affinity determination. From the binding affinity studies of both compounds tested against mouse R2 protein, we obtained $K_D$ values in the low $\mu$M range, with $K_D$s of 2.7 ± 0.4 $\mu$M and 3.3 ± 0.4 $\mu$M for $H_2L^2$ and 3, respectively (Figure 9). Regarding the proligand $H_2L^2$, these values are in the same general range established by the enzymatic IC$_{50}$ values for the proligand (also reported in this paper to be between 4.2 and 5.4 $\mu$M for HeLa, K562, A549 and LS-174 cell lines). Regarding the copper(II) complex 3, however, although the $K_D$ values are equivalent to those
obtained for $\text{H}_2\text{L}^2$, the complex shows lower selectivity towards cancer cells. Interestingly, $\text{H}_2\text{L}^2$ and 3 are predicted to have the same binding affinity in line with the affinity measurements. Despite these differences, both compounds show a significant effect on the $\text{Y}^\bullet$ destruction in the mouse R2 protein, as seen from the kinetic monitoring of the $\text{Y}^\bullet$ concentration by EPR (Figures 10 and 11). The structural nature of the binding interactions of the investigated compounds and R2 protein are not resolved from the MST assay, therefore, molecular modeling of the R2 protein and the compounds $\text{H}_2\text{L}^2$ and 3, was also performed in this study.

![Binding curves for the interaction of $\text{H}_2\text{L}^2$ (A) and 3 (B) with mouse R2.](image)

**Figure 9.** Binding curves for the interaction of $\text{H}_2\text{L}^2$ (A) and 3 (B) with mouse R2. The changes in fluorescence signals were fitted (lines) to yield $K_D$ values of $2.7 \pm 0.4 \mu\text{M}$ and $3.3 \pm 0.4 \mu\text{M}$ for $\text{H}_2\text{L}^2$ and 3, respectively.

**Interaction with Ribonucleotide Reductase – Effect on $\text{Y}^\bullet$.** The effect of the proligand $\text{H}_2\text{L}^2$ and
complex 3 on the Y• in mouse R2 protein was tested by low-temperature EPR spectroscopy. X-band (9.4 GHz) absorption derivative spectra were recorded at 30 K. Highly purified iron-reconstituted R2 protein in buffer containing 1% DMSO was incubated with the two compounds, along with the control sample (blank) for 1 min at 298 K. For the first set of EPR measurements, 55 µM R2 monomer was incubated with 40 µM of each compound, whereas for the second set of EPR measurements, 50 µM protein was incubated with an equal concentration of compounds, yielding a 1:1 molar ratio. In the latter case, DTT was also added in two steps, where spectra recorded after 6.5 and 146 min incubation time correspond to sample incubations after addition of 0.5 and 1 mM dithiothreitol (DTT), respectively. Between each recording of spectra, samples were simultaneously thawed, incubated for the indicated times (see Table 3 for total times of incubation), and quickly refrozen in liquid nitrogen. As seen in Table 3 and Figures 10 and 11, the effect of H₂L₂ and 3 on the Y• signal is clearly seen in both cases, indicating a faster destruction of the Y• as compared to the blank samples. Furthermore, the depletion of the signal is even more evident in the presence of DTT, where a distinct reduction of the signal is especially observed after the addition of 1 mM DTT, recorded after a total incubation time of 146 min at 298 K. In comparison, the Y• signal is slowly decreased at the equivalent incubation time in the blank sample. Previous studies have shown that 1% DMSO in the samples has no effect on the natural decay of Y•, and is not accounted for in this study. The decay of the Y• is shown in Figures 10 and 11, for measurements in the presence and in the absence of DTT. As seen from the EPR experiments, H₂L₂ shows the greatest effect on the Y•, as compared to 3, resulting in the lowest Y• content after 1226 min total incubation time at room temperature. This is also observed from the UV–vis spectroscopy, where the peak at 408 nm, characteristic of a tyrosyl radical, was followed. The Y• seems to be quenched to a larger extent in the presence of H₂L₂ than in the presence 3 (Figure 12). As both compounds bind to the R2 protein with low µM affinities, and show significant effects on Y• quenching, these results taken together strongly indicate that both H₂L₂ and 3 serve as effective R2 inhibitors.

Table 3. Mouse R2 tyrosyl radical (Y•) content in reconstituted R2 protein and H₂L₂ and 3, after different incubation times at 298 K.

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>R2 (blank)</th>
<th>R2 + H₂L₂</th>
<th>R2 + 3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Y•/R2⁺ %  †</td>
<td>Y•/R2⁺ % †</td>
<td>Y•/R2⁺ % †</td>
</tr>
<tr>
<td>Run #1§</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>0.45</td>
<td>0.44</td>
<td>0.42</td>
</tr>
<tr>
<td></td>
<td>90.0</td>
<td>97.8</td>
<td>93.3</td>
</tr>
<tr>
<td>16</td>
<td>0.41</td>
<td>0.39</td>
<td>0.38</td>
</tr>
<tr>
<td></td>
<td>91.1</td>
<td>86.7</td>
<td>84.8</td>
</tr>
</tbody>
</table>
Run #2

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>6.5 (+ 0.5 mM DTT)</th>
<th>26</th>
<th>86</th>
<th>146 (+ 1 mM DTT)</th>
<th>1226</th>
</tr>
</thead>
<tbody>
<tr>
<td>116</td>
<td>0.34</td>
<td>0.34</td>
<td>0.3</td>
<td>0.3</td>
<td>0.22</td>
<td>0.02</td>
</tr>
<tr>
<td>446</td>
<td>0.17</td>
<td>0.29</td>
<td>0.3</td>
<td>0.3</td>
<td>0.22</td>
<td>0.02</td>
</tr>
<tr>
<td>1450</td>
<td>0.09</td>
<td>0.29</td>
<td>0.3</td>
<td>0.3</td>
<td>0.22</td>
<td>0.02</td>
</tr>
<tr>
<td>446</td>
<td>0.17</td>
<td>0.29</td>
<td>0.3</td>
<td>0.3</td>
<td>0.22</td>
<td>0.02</td>
</tr>
<tr>
<td>1450</td>
<td>0.09</td>
<td>0.29</td>
<td>0.3</td>
<td>0.3</td>
<td>0.22</td>
<td>0.02</td>
</tr>
<tr>
<td>116</td>
<td>0.34</td>
<td>0.34</td>
<td>0.3</td>
<td>0.3</td>
<td>0.22</td>
<td>0.02</td>
</tr>
<tr>
<td>446</td>
<td>0.17</td>
<td>0.29</td>
<td>0.3</td>
<td>0.3</td>
<td>0.22</td>
<td>0.02</td>
</tr>
<tr>
<td>1450</td>
<td>0.09</td>
<td>0.29</td>
<td>0.3</td>
<td>0.3</td>
<td>0.22</td>
<td>0.02</td>
</tr>
</tbody>
</table>

† Yield of tyrosyl radical (Y•)/R2 monomer
‡ Percent compared to untreated R2 (blank) sample at time 1 min
§ First set of EPR measurements (molar ratio of ~ 0.75 tested compound/R2 monomer)
¶ Second set of EPR measurements, with addition of DTT (molar ratio of 1 tested compound/R2 monomer)

**Figure 10.** The effect of $\text{H}_2\text{L}^2$ and 3 on mouse R2 tyrosyl radical (Y•) content. (A) Y• yield/R2 monomer in samples containing 55 µM R2 and 40 µM tested compound, measured after 1, 16, 116, 446, and 1450 min total incubation time at 298 K. (B) X-band EPR spectra showing decreasing Y• content following increasing incubation times at 298 K. (C) EPR spectra of R2 (black trace), R2 with $\text{H}_2\text{L}^2$ (red trace), and R2 with 3 (blue trace), recorded after a total incubation time of 1450 min at 298 K. $\text{H}_2\text{L}^2$ shows the largest effect on the quenching of Y•.
Figure 11. The effect of $\text{H}_2\text{L}_2$ and 3 on mouse R2 tyrosyl radical (Y•) content in the presence of DTT. (A) Y• yield/R2 monomer in samples containing 50 µM R2 and 50 µM tested compound, measured after 1, 6.5, 26, 86, 146, and 1226 min total incubation time at 298 K. 0.5 mM DTT and 1 mM DTT was added to the samples prior to incubation at 298 K for 6.5 min and 146 min in total, respectively. (B) X-band EPR spectra showing decreasing Y• content following increasing incubation times at 298 K. A substantial loss of the Y• content is observed after the addition of 1 mM DTT in samples containing both compounds. (C) EPR spectra of R2 (black trace), R2 with $\text{H}_2\text{L}_2$ (red trace), and R2 with 3 (blue trace), containing a total concentration of 1.5 mM DTT, recorded after a total incubation time of 1226 min at 298 K. $\text{H}_2\text{L}_2$ shows the largest effect on the quenching Y•, as seen for EPR experiments without the addition of DTT. However, the effect of 3 is in this case greater than observed in R2 samples where DTT was not added (see Figure 10 and Table 2).

Figure 12. UV–vis spectra of mouse R2 with $\text{H}_2\text{L}_2$ (A) and 3 (B). In both (A) and (B), the different spectra represent the following: 1) 6 µM compound; 2) 30 µM apo-R2; 3) 30 µM reconstituted R2 (R2-Fe(III)2-Y•); 4) as 3 + 6 µM compound (10 min incubation); 5) as 4 + 1 mM DTT (5 min incubation); 6) as 5 + 24 µM compound + 1 mM DTT (10 min incubation).
Conclusions
A series of six iminodiacetate-thiosemicarbazone hybrids and six dicopper(II) complexes, the latter resulting from reactions of copper(II) salts with the proligands, have been synthesized and characterized by X-ray diffraction, analytical and spectroscopic techniques. All compounds were assayed for antiproliferative activity in four cancer and one noncancerous cell lines showing moderate to high cytotoxicity often exceeding that of the clinical drug cisplatin. There are no clear-cut structure–activity relationships to be mentioned. The effect of copper(II) coordination is manifested in a divergent way. In some cases, as for H2L1, binding of copper(II) results in a 2- to 10-fold enhancement of antiproliferative activity, while in the case of H2L3, a 2- to 14-fold decrease of activity is observed in cancer cell lines. In addition, H2L4 and H2L5 underwent chemical transformations induced by copper(II) coordination, resulting in formation of new ligands (HL4)− and (HL5)−. Therefore, the proligands H2L4 and H2L5 and their corresponding copper(II) complexes are not directly comparable. It is also worth mentioning the effect of thiomethylation of the thiosemicarbazide moiety on cytotoxicity, which is divergent for organic hybrids and dicopper(II) complexes. Compound 6 is by a factor of 2 in average less active than 1, while H2L6 is generally more cytotoxic than H2L1 in cancer cell lines. The selectivity of H2L2 and 3 for cancer vs noncancerous cells deserves to be mentioned as well. Taking into account the observed selectivity for cancer cells, both these compounds and for comparison reasons, complex 2 and proligand H2L3 were chosen for further studies into the mechanism of antiproliferative activity, and for interaction studies with the R2 protein of RNR. The absence of early and late apoptotic populations established by flow cytometry dual staining of K562 cells with annexin V-FITC and PI and cell cycle analysis indicated that other mechanisms of antiproliferative activity are involved in the case of complex 2. The likelihood of binding of H2L2 and 3 to mouse R2 RNR was suggested by molecular docking calculations. Binding affinity measurements performed by microscale thermophoresis afforded K_D values in the low µM range indicating formation of adducts and possible inhibition of RNR. Indeed, both compounds showed a marked effect on destruction of the tyrosyl radical in mouse R2 protein monitored by kinetic measurements of the Y• concentration by EPR and UV–vis spectroscopies. The effect was more pronounced in the presence of DTT, as seen from EPR measurements. The compounds investigated in this work deserve further investigation into the mechanisms of antiproliferative and R2 inhibition activities as potential anticancer drugs.

Experimental Section
Materials. Dimethyliminodiacetate hydrochloride (Alfa Aesar), sodium hydrogen carbonate (Alfa Aesar), thiosemicarbazide (Alfa Aesar), 4,4'-dimethyl-thiosemicarbazide (Alfa Aesar), (trimethylsilyl)methylamine (Aldrich), copper(II) chloride dihydrate and copper(II) acetate monohydrate were used as received. Tetrahydrofuran (THF), dichloromethane (DCM), chloroform, diethylether, ethanol and methanol were received from Acros. 4-N-pyrrolidine-thiosemicarbazide, S-methylisothiosemicarbazide hydroiodide, 4-(1-naphthyl)-3-thiosemicarbazide and S-methyl-hydrazinecarbodithioate were synthesized by following literature procedures. 3-(Chloromethyl)-2-hydroxy-5-methylbenzaldehyde (A) was prepared from 5-methyl-2-hydroxy-benzaldehyde according to a procedure reported elsewhere. 33

(Trimethylsilyl)methyl thiosemicarbazide has been prepared by reacting S-methylhydrazinecarbodithioate (2.00 g, 16.5 mmol) with (trimethylsilyl)methylamine (2 mL, 15 mmol) in ethanol (40 mL) at reflux overnight, followed by chromatographic separation using chloroform as eluent. Yield: 1.34 g, 52%. 1H NMR (DMSO-\textit{d}_6, \delta, ppm): 8.49 (s, 1H, NH), 7.58 (s, 1H, NH), 4.46 (s, 2H, NH\textsubscript{2}), 3.04 (d, J = 5.7 Hz, 2H, CH\textsubscript{2}), 0.06 (s, 9H, CH\textsubscript{3}). ESI-MS (methanol): positive \textit{m/z} 178 [M + H]+. ATR-IR, cm\textsuperscript{–1}: 3261m, 3242m, 2955w, 2897w, 1553s, 1502m, 1478w, 1414m, 1373w, 1288m, 1250s, 1202m, 1055m, 922w, 843vs, 764m, 696m, 640s, 592m.

Synthesis of proligands

Dimethyl-2,2'-(3-formyl-2-hydroxy-5-methylbenzyl)-azanediyl)diacetate (B). To a solution of dimethyliminodiacetate hydrochloride (1.00 g, 5.00 mmol) in DCM (25 mL) a solution of 3-(chloromethyl)-2-hydroxy-5-methylbenzaldehyde (A) (0.90 g, 5.00 mmol) in THF (25 mL) and triethylamine (3 mL) were added. The color changed to yellow. The reaction mixture was stirred at room temperature overnight. The precipitate formed was filtered off. The filtrate was concentrated under reduced pressure to afford yellow oil, which was dissolved in DCM (30 mL) and poured into a saturated aqueous solution of sodium hydrogen carbonate (75 mL). The organic layer was separated and the aqueous solution was extracted with DCM (2 \times 10 mL). The combined organic extracts were concentrated under reduced pressure to give yellow oil which was dried in vacuo. Yield: 1.3 g, 83%. 1H NMR (400.10 MHz, CDCl\textsubscript{3}, \delta, ppm): 10.66 (s, 1H, -OH), 10.16 (s, 1H, CH=O), 7.41 (s, 1H, Ar H), 7.34 (s, 1H, Ar H), 3.99 (s, 2H, CH\textsubscript{2}), 3.74 (s, 6H, CH\textsubscript{3}), 3.60 (s, 4H, CH\textsubscript{2}), 2.32 (s, 3H, CH\textsubscript{3}). ESI–MS (methanol): positive \textit{m/z} 310 [M + H]+, 332 [M + Na]+. ATR–IR, cm\textsuperscript{–1}: 3290vw, 2945m,
To a solution of the aldehyde **B** (0.31 g, 1.00 mmol) in methanol (5 mL) a hot solution of thiosemicarbazide (0.09 g, 1.00 mmol) in water (5 mL) was added. The mixture was stirred to reflux for 1 h and a yellow precipitate was formed. The solid was filtered off, washed with cold methanol/water 1:1 (3 × 5 mL), then with cold methanol (3 mL) and diethylether (3 mL) and dried *in vacuo*. Single crystals of X-ray diffraction quality were obtained by recrystallization of the raw product from methanol/chloroform 1:1. Yield: 0.35 g, 93%. Anal. Calcd for C₁₆H₂₂N₄O₅S (Mr 382.43): C, 50.25; H, 5.80; N, 14.65; S, 8.38. Found: C, 50.70; H, 5.80; N, 14.55; S, 8.12. ¹H NMR 400.13 MHz (DMSO-d₆, δ, ppm): 11.42 (s, 1H, NH), 9.76 (s, 1H, OH), 8.38 (s, 1H, H7), 8.12 (s, 1H, NH), 7.93 (s, 1H, NH), 7.75 (s, 1H, H5), 6.91 (s, 1H, H3), 3.86 (s, 2H, H10), 3.66 (s, 6H, H13), 3.54 (s, 4H, H11), 2.21 (s, 3H, H9). ¹³C NMR 100.6 MHz (DMSO-d₆, δ, ppm): 177.6 (C8), 171.1 (C12), 153.7 (C1), 139.2 (C7), 132.0 (C3), 127.7 (C4), 126.0 (C5), 122.5 (C2), 120.2 (C6), 54.8 (C10), 53.3 (C11), 51.6 (C13), 19.9 (C9). ESI–MS (methanol), positive m/z 383 [M + H]⁺, 405 [M + Na]⁺.

**H₂L₁**. To a solution of **B** (0.31 g, 1.00 mmol) in methanol (5 mL) a hot solution of 4,4’-dimethyl-thiosemicarbazide (0.12 g, 1.00 mmol) in water (5 mL) was added. The mixture was stirred at reflux for 1 h. Yellow crystals of X-ray diffraction quality were obtained when the mixture has cooled to room temperature. The crystals were filtered off, washed with water (3 × 5 mL) and dried in air at room temperature. Yield: 0.32 g, 88%. Anal. Calcd for C₁₈H₂₆N₄O₅S·0.5 H₂O (Mr 419.49): C, 51.54; H, 6.49; N, 13.36; S, 7.64. Found: C, 51.24; H, 6.47; N, 13.34; S, 7.57. ¹H NMR 400.13 MHz (DMSO-d₆, δ, ppm): 11.73 (s, 1H, OH), 11.22 (s, 1H, NH), 8.47 (s, 1H, H7), 7.19 (d, J = 1.6 Hz, 1H, H3), 7.09 (d, J = 2.0 Hz, 1H, H5), 3.86 (s, 2H, H10), 3.62 (s, 6H, H13), 3.54 (s, 4H, H11), 3.30 (s, 6H, H17, 18), 2.25 (s, 3H, H9). ¹³C NMR 100.6 MHz (DMSO-d₆, δ, ppm): 179.1 (C8), 171.2 (C12), 153.3 (C1), 146.5 (C7), 132.2 (C3), 129.1 (C5), 127.0 (C4), 124.9 (C2), 117.7 (C6), 53.8 (C11), 51.1 (C13), 50.9 (C10), 41.0 (C17, C18), 20.0 (C9). ESI–MS (methanol), positive: m/z 433 [M + Na]⁺.

**H₂L₂**. To a solution of **B** (0.31 g, 1.00 mmol) in methanol (5 mL) a hot solution of 4,4’-dimethyl-thiosemicarbazide (0.12 g, 1.00 mmol) in water (5 mL) was added. The mixture was stirred at reflux for 1 h. Yellow crystals of X-ray diffraction quality were obtained when the mixture has cooled to room temperature. The crystals were filtered off, washed with water (3 × 5 mL) and dried in air at room temperature. Yield: 0.32 g, 88%. Anal. Calcd for C₁₈H₂₆N₄O₅S·0.5 H₂O (Mr 419.49): C, 51.54; H, 6.49; N, 13.36; S, 7.64. Found: C, 51.24; H, 6.47; N, 13.34; S, 7.57. ¹H NMR 400.13 MHz (DMSO-d₆, δ, ppm): 11.73 (s, 1H, OH), 11.22 (s, 1H, NH), 8.47 (s, 1H, H7), 7.19 (d, J = 1.6 Hz, 1H, H3), 7.09 (d, J = 2.0 Hz, 1H, H5), 3.86 (s, 2H, H10), 3.62 (s, 6H, H13), 3.54 (s, 4H, H11), 3.30 (s, 6H, H17, 18), 2.25 (s, 3H, H9). ¹³C NMR 100.6 MHz (DMSO-d₆, δ, ppm): 179.1 (C8), 171.2 (C12), 153.3 (C1), 146.5 (C7), 132.2 (C3), 129.1 (C5), 127.0 (C4), 124.9 (C2), 117.7 (C6), 53.8 (C11), 51.1 (C13), 50.9 (C10), 41.0 (C17, C18), 20.0 (C9). ESI–MS (methanol), positive: m/z 433 [M + Na]⁺.

**UV–vis (methanol), λ_{max} (ε, M⁻¹ cm⁻¹):** 224sh, 301 (17500), 310 (18033), 339 (19432), 392 sh at 2.4 × 10⁻⁵ M. ATR–IR, cm⁻¹: 3448m, 3335m, 3165w, 3026w, 2953w, 2916w, 2856w, 1724vs, 1616w, 2642m, 2625m, 588w.
To a solution of \( B \) (0.31 g, 1.00 mmol) in methanol (5 mL) a hot solution of 4\( N \)-pyrrolidine-thiosemicarbazide (0.15 g, 1.00 mmol) in methanol/water 1:2 (15 mL) was added. The resulting mixture was stirred at reflux for 1 h and a yellow precipitate was formed. The solid was filtered off, washed with cold methanol/water 1:1 (3 \( \times \) 5 mL), then with cold methanol (3 mL) and diethylether (3 mL) and dried \textit{in vacuo}. Single crystals of X-ray diffraction quality were obtained by recrystallization of the raw product from methanol. Yield: 0.40 g, 91%. Anal. Calcd for \( \text{C}_{20}\text{H}_{28}\text{N}_{4}\text{O}_{5}\text{S} \left( M \right. \text{r 436.52}) \): C, 55.03; H, 6.46; N, 12.83; S, 7.35. Found: C, 54.80; H, 6.43; N, 12.50; S, 7.08. \( ^1\text{H} \) NMR 400.13 MHz (DMSO-\( \text{d}_6 \), \( \delta \), ppm): 11.56 (s, 1H, OH), 10.98 (s, 1H, NH), 8.45 (s, 1H, H7), 7.18 (d, \( J = 1.2 \) Hz, 1H, H3), 7.08 (d, \( J = 1.6 \) Hz, 1H, H5), 3.88 (s, 2H, H10), 3.68 (t, \( J = 6.4 \) Hz, 4H, H17, H20), 3.63 (s, 6H, H13), 3.54 (s, 4H, H11), 2.26 (s, 3H, H9), 1.95 (t, \( J = 6.4 \) Hz, 4H, H18a, H19a). \( ^{13}\text{C} \) NMR 100.6 MHz (DMSO-\( \text{d}_6 \), \( \delta \), ppm): 175.9 (C8), 170.8 (C12), 153.1 (C1), 145.7 (C7), 131.8 (C3), 128.6 (C5), 126.8 (C4), 124.7 (C2), 117.7 (C6), 53.8 (C11), 51.2 (C10), 50.8 (C13), 50.1 (C17, C20), 44.4 (C18a, C19a), 19.7 (C9). ESI–MS (methanol), positive \( m/z \) 459 [M + Na\(^+\)]. UV–vis (methanol), \( \lambda_{\text{max}} \) (\( \epsilon, M^{-1}\text{cm}^{-1} \)): 206 (28864), 225 (27477), 288 (21620), 336 (14430), 394\( _{\text{sh}} \) at \( 2.1 \times 10^{-5} \) M. ATR–IR, cm\(^{-1}\): 3290m, 3084vw, 2947w, 2862w, 1726vs, 1651vw, 1616w, 1551s, 1460s, 1421s, 1358m, 1340s, 1296vs, 1246m, 1215vs, 1190vs, 1157s, 1128s, 1038m, 999s, 941m, 908m, 868m, 785m, 752m, 710m, 675m, 646m, 575w.

To a solution of \( B \) (0.31 g, 1.00 mmol) in methanol (5 mL) a solution of (trimethylsilyl)methylthiosemicarbazide (0.17 g, 1.00 mmol) in water/methanol mixture 2:1 (15 mL) was added and the mixture was stirred at reflux for 1 h. The yellow precipitate was filtered off, washed with cold methanol/water 1:1 (3 \( \times \) 5 mL), then with cold methanol (3 mL) and diethylether (3 mL) and dried \textit{in vacuo}. Single crystals were obtained by recrystallization of the raw product from methanol/diethylether 1:2. Yield: 0.36 g, 77%. Anal. Calcd for \( \text{C}_{20}\text{H}_{32}\text{N}_{4}\text{O}_{5}\text{SSi} \left( M \right. \text{r 468.64}) \): C, 51.26; H, 6.88; N, 11.96; S, 6.84. Found: C, 51.41; H, 6.88; N, 11.70; S, 6.67. \( ^1\text{H} \) NMR 500.13 MHz (DMSO-\( \text{d}_6 \), \( \delta \), ppm): 11.34 (s, 1H, NH), 9.80 (s, 1H, OH), 8.36 (s, 1H, H7), 8.19 (t, \( J = 6.0 \) Hz, 1H, NH), 7.59 (s, 1H, H5), 6.93 (s, 1H, H3), 3.87 (s, 2H, H10), 3.65(s, 6H, H13), 3.54 (s, 4H, H11), 3.21 (d, \( J = 6.0 \) Hz, 2H, H17), 2.22 (s, 3H, H9), 0.11 (s, 9H, H18-H20). \( ^{13}\text{C} \) NMR 125.7 MHz (DMSO-\( \text{d}_6 \), \( \delta \), ppm): 176.3 (C8), 171.2 (C12), 153.5 (C1), 138.7 (C7), 131.9 (C3), 127.6 (C4), 125.8 (C5), 122.7 (C2), 120.3 (C6), 54.6 (C10), 53.3 (C11), 51.6 (C13), 34.2 (C17), 20.1 (C9), −1.8 (C18-C20).
ESI–MS (methanol), positive $m/z$ 491 [M + Na]$^+$. UV–vis (methanol), $\lambda_{\text{max}}$ ($\epsilon$, M$^{-1}$cm$^{-1}$): 235 (3184), 300 (18694), 313 (21691), 342 (33059), 355$_{\text{sh}}$, 398$_{\text{sh}}$ at 2.3 $\times$ 10$^{-5}$ M. ATR–IR, cm$^{-1}$: 3325w, 2955w, 1732s, 1607w, 1529s, 1480w, 1429m, 1329s, 1246s, 1211s, 1184s, 1156m, 1111s, 1072m, 1013m, 953m, 895w, 847vs, 758m, 700m, 650m, 582m.

H$_2$L$^5$. To a solution of B (0.31 g, 1.00 mmol) in methanol (5 mL) a solution of 4-(1-naphthyl)-3-thiosemicarbazide (0.21 g, 1.00 mmol) in methanol/water 1:2 (15 mL) was added. The resulting mixture was stirred at reflux for 1 h and a yellow precipitate was formed. The product was filtered off, washed with cold methanol/water 1:1 (3 $\times$ 5 mL), then with cold methanol (3 mL) and diethylether (3 mL) and dried in vacuo. Single crystals were obtained by recrystallization of the raw product from acetonitrile/chloroform 1:1. Yield: 0.42 g, 84%. Anal. Calcd for C$_{26}$H$_{28}$N$_4$O$_5$S·0.3H$_2$O ($M_r$ 513.99): C, 60.76, H, 5.61, N, 10.90, S, 6.24. Found: C, 61.10, H, 5.51, N, 10.54, S, 5.91. $^1$H NMR 400.13 MHz (DMSO-d$_6$, $\delta$, ppm): 11.93 (s, 1H, NH), 10.32 (s, 1H, NH), 9.83 (s, 1H, OH), 8.57 (s, 1H, H7), 8.01–7.52 (m, 8H, H5, H18-25), 6.93 (s, 1H, H3), 3.89 (s, 2H, H10), 3.67 (s, 6H, H13), 3.57 (s, 4H, H11), 2.20 (s, 3H, H9). $^{13}$C NMR 100.6 MHz (DMSO-d$_6$, $\delta$, ppm): 177.6 (C8), 171.2 (C12), 153.8 (C1), 139.6 (C7), 133.7 (C3), 126.4 (C5), 135.8, 132.2, 130.7, 127.9, 127.7, 126.9, 126.0, 125.4, 123.4 (C4, C18-C25), 122.5 (C2), 120.3 (C6), 54.9 (C10), 53.3 (C11), 51.6 (C13), 20.0 (C9). ESI–MS (methanol), positive $m/z$ 531 [M + Na]$^+$. UV–vis (methanol), $\lambda_{\text{max}}$ ($\epsilon$, M$^{-1}$cm$^{-1}$): 221 (44904), 305 (16000), 314 (16570), 344 (21186) at 2 $\times$ 10$^{-5}$ M. ATR–IR, cm$^{-1}$: 3331w, 3209m, 3045w, 3013w, 2955, 2885w, 2956w, 1720s, 1597w, 1531s, 1487s, 1431s, 1373m, 1288s, 1211vs, 1088m, 999s, 957m, 868m, 768m, 731m, 679m, 582m.

H$_2$L$^6$. To a solution of B (0.64 g, 2.00 mmol) in methanol (5 mL) a solution of S-methyl-isothiosemicarbazide hydroiodide (0.47 g, 2.0 mmol) in methanol/water 1:2 (15 mL) was added. The resulting mixture was stirred at reflux for 1 h, then a solution of sodium hydrogen carbonate (0.17 g, 2.0 mmol) in water (5 mL) was added. A yellow oil was formed which was decanted, washed with cold methanol/water 1:1 (3 mL), dissolved in DCM (10 mL) and extracted with water (3 $\times$ 30 mL). The organic layer was concentrated under reduced pressure and dried in vacuo to afford yellow oil. Single crystals of X-ray diffraction quality were obtained by recrystallization of the raw product from methanol/water 1:1. Yield: 0.63 g, 76%. Anal. Calcd for C$_{17}$H$_{24}$N$_4$O$_5$S·0.2MeOH ($M_r$ 402.87): C, 51.28; H, 6.20; N, 13.91; S, 7.96. Found: C, 51.51; H, 6.23; N, 13.56; S, 7.60. $^1$H NMR 400.13 MHz (DMSO-d$_6$, $\delta$, ppm): 9.63 (s, 2H, NH2), 8.68 (s, 1H, H7), 7.82 (s, 1H, H5), 7.05 (s, 1H, H3), 3.94 (s, 2H, H10), 3.63 (s, 6H, H13), 3.60 (s, 4H, H11), 2.71 (s, 3H, H17), 2.21 (s, 3H, H9). $^{13}$C
NMR 100.6 MHz (DMSO-d6, δ, ppm): 171.0 (C12), 166.1 (C8), 155.2 (C1), 149.2 (C7), 135.0 (C3), 128.8 (C4), 127.5 (C5), 122.6 (C2), 119.2 (C6), 55.3 (C10), 53.8 (C11), 52.2 (C13), 20.2 (C9), 13.7 (C17).

ESI–MS (methanol), positive m/z 419 [M + Na]⁺, 815 [2·M + Na]⁺. UV–vis (methanol), λ_{max} (ε, M⁻¹ cm⁻¹): 226 (3777), 298 (21292), 311 (22983), 341 (26666), 353 (23807) at 1.3 × 10⁻⁵ M.

ATR–IR, cm⁻¹: 3456w, 3344w, 3124vw, 2999, 2951w, 2864, 1736vs, 1610s, 1524vs, 1460s, 1437s, 1377m, 1337m, 1288s, 1252s, 1202vs, 1153vs, 1007s, 973s, 864m, 744m, 667w, 629w, 577w.

**Synthesis of copper(II) complexes**

[Cu(HL₁)Cl₃]·2H₂O (1·2H₂O). To a suspension of H₂L₁ (0.19 g, 0.5 mmol) in methanol (10 mL) a solution of copper(II) chloride dihydrate (0.17 g, 1 mmol) in methanol (5 mL) was added. The color changed to dark brown. The mixture was stirred at 60 °C for 1 h, then cooled to room temperature and left for crystallization at room temperature. X-ray diffraction-quality single crystals were obtained after 48 h, washed with cold methanol and dried in air at room temperature. Yield: 0.15 g, 45%. Anal. Calcd for C₁₆H₂₁Cl₃Cu₂N₄O₅S·2H₂O (M, 650.97), %: C, 29.52; H, 3.87; N, 8.61; S, 4.90. Found, % : C, 29.73; H, 3.66; N, 8.32; S, 4.84. Solubility in water: ≥ 8.00 mg/mL. ESI–MS (methanol), positive m/z 543 [Cu²⁺(L₁)Cl]⁺, 480 [Cu²⁺(HL₁)Cl + H]⁺, 444 [Cu²⁺(L₁) + H]⁺. UV–vis (methanol), λ_{max} (ε, M⁻¹ cm⁻¹): 202 (26316), 234 (18471), 276 (13604), 319 (14583), 374 (12527) at 1.1 × 10⁻⁵ M, 660 (191) at 1.3 × 10⁻³ M. ATR–IR, cm⁻¹: 3564w, 3394vw, 3269m, 3117w, 2953w, 2918w, 1713vs, 1649s, 1618s, 1566vs, 1460s, 1433s, 1366m, 1344m, 1271m, 1238s, 1169s, 1101m, 1068m, 1029, 968s, 901m, 858s, 814s, 777m, 731m, 640m, 590s.

[Cu₂(L₂)(OMe)] (2). To a suspension of H₂L₂ (0.20 g, 0.5 mmol) in methanol (10 mL) a suspension of copper(II) acetate monohydrate (0.20 g, 1.0 mmol) in methanol (10 mL) was added. The color changed to dark brown. The mixture was stirred at room temperature for 1 h, then filtered and allowed to stand at room temperature. X-ray diffraction-quality single crystals were filtered off after 48 h, washed with cold methanol and dried in air at room temperature. Yield: 0.14 g, 25%. Anal. Calcd for C₁₈H₂₄Cu₂N₄O₆S (M, 551.56): C, 39.20, H, 4.39, N, 10.16, S, 5.81 Found: C, 39.20, H, 4.47, N, 9.85 S, 5.65. ESI–MS (methanol), positive m/z 573 [Cu₂(L₂)(OMe) + Na]⁺, 1125 [{Cu₂(L₂)(OMe)}₂ + Na]⁺. UV–vis (methanol), λ_{max} (ε, M⁻¹ cm⁻¹): 204 (54190), 237 (29115), 280 (15265), 324 (26840), 337 (27366), 376 (28198), at 1.2 × 10⁻⁵ M, 638 (145) at 1.5 × 10⁻³ M. ATR–IR, cm⁻¹: 2930w, 2808w, 1720m, 1664s, 1639s, 1591w, 1562m, 1510s, 1462m, 1414s, 1380m, 1342m, 1300w, 1265m, 1230m, 1202m, 1182w, 1131m, 1107w, 1078m, 1022s, 955m, 914m, 868m, 822m, 764m, 731s, 648s, 611vs, 581vs.
[Cu2(L3)(OMe)] (3). To a suspension of H2L3 (0.26 g, 0.6 mmol) in methanol (10 mL) a suspension of copper(II) acetate monohydrate (0.23 g, 1.20 mmol) in methanol (10 mL) was added. The color changed to dark brown. The mixture was stirred at room temperature for 1 h, then filtered and allowed to stand at room temperature. X-ray diffraction-quality single crystals were filtered off after 72 h, washed with methanol and dried in air at room temperature. Yield: 0.14 g, 41%. Anal. Calcd for C20H27Cu2N4O6S (M 578.61): C, 41.52, H, 4.70, N, 9.68, S, 5.48. Found: C, 41.54, H, 4.61, N, 9.57, S, 5.48. ESI–MS (methanol), positive m/z 577 [Cu2(L3)(OMe) + H]+, 599 [Cu2(L3)(OMe) + Na]+, 1177 [{Cu2(L3)(OMe)}2 + Na]+. UV–vis (methanol), λmax (ε, M–1 cm–1): 200 (31051), 238 (23933), 279 (13447), 323 (19602), 335 (19799) at 0.9 × 10–5 M, 638 (145) at 1.4 × 10–3 M. ATR–IR, cm–1: 2966w, 2918w, 2868w, 2812w, 1726s, 1659s, 1593m, 1564m, 1487s, 1448s, 1394m, 1329s, 1273s, 1217s, 1184m, 1107w, 1078m, 1032s, 1007s, 962m, 906s, 862m, 822s, 710s, 685m, 646s, 613s, 579s.

[Cu2(HL4)Cl3] (4). To a solution of H2L4 (0.117 g, 0.25 mmol) in methanol (5 mL) a solution of copper(II) chloride dihydrate (0.085 g, 0.5 mmol) in methanol (3 mL) was added. The resulting mixture was stirred at 50 °C overnight, then was allowed to evaporate at room temperature. X-ray diffraction-quality single crystals were filtered off after 48 h, washed with methanol and dried in air at room temperature. Yield: 0.10 g, 63%. Anal. Calcd for C18H25Cl3Cu2N4O6S (M 658.93): C, 32.81, H, 3.82, N, 8.50, S, 4.78. Found: C, 32.82, H, 3.97, N, 8.24, S, 4.78. Solubility in water: ≥ 8.00 mg/mL. ESI–MS (methanol), positive m/z 587 [CuII2(L4)Cl]+, 488 [CuII(HL4)]+. UV–vis (methanol), λmax (ε, M–1 cm–1): 222 (13564), 234 (13321), 285 (14254), 314 (13342) 380 (11554) at 4.2 × 10–5 M, 634 (178) at 2.5 × 10–3 M. ATR–IR, cm–1: 3180m, 3123w, 3026m, 2968w, 2935w, 2820vw, 1720s, 1612w, 1570vs, 1535s, 1456m, 1431s, 1360s, 1319s, 1276s, 1221vs, 1074vs, 962s, 908m, 860, 812m, 795m, 694s, 594m.

[Cu2(HL5)Cl3] (5). To a suspension of H2L5 (0.51 g, 1.00 mmol) in methanol (10 mL) a solution of copper(II) chloride dihydrate (0.17 g, 1.00 mmol) in methanol (5 mL) was added. The color changed to dark brown. The mixture was stirred at 60 °C for 1 h, then cooled to room temperature and left for crystallization at room temperature. X-ray diffraction-quality single crystals were filtered off after 48 h, washed with methanol and dried in air at room temperature. Yield: 0.15 g, 22%. Anal. Calcd for C26H25Cl3Cu2N4O5S (M 739.02): C, 42.26 H, 3.41, N, 7.58, S, 4.34 Found: C, 42.18, H, 3.76, N, 7.28 S, 4.13. UV–vis (methanol), λmax (ε, M–1 cm–1): 227 (17591), 258 (11735), 346 (4415), 417
(6893) at $1.8 \times 10^{-5}$ M, 696 (104) at $1.7 \times 10^{-3}$ M. ATR–IR, cm$^{-1}$: 3223m, 3078, 3020vw, 2949w, 2916vs, 1720, 1614w, 1547s, 148s1, 1443s, 1377s, 1290s, 1248vs, 1229s, 1121s, 1095m , 1032m, 1005m, 987w, 897m, 860s, 80s0, 775m, 735m, 671m, 617m, 565vw.

$[\text{Cu}_2(\text{L}^6)\text{Cl}_3] \cdot 0.5\text{H}_2\text{O}$ (6·0.5H$_2$O). To a solution of H$_2$L$_6$ (0.49 g, 1.2 mmol) in methanol (10 mL) a solution of copper(II) chloride dihydrate (0.31 g, 1.8 mmol) in methanol (5 mL) was added. The color changed to dark brown. The mixture was heated at 60 °C for 1 h and allowed to stand at room temperature for crystallization. The crystals were filtered off after 24 h, washed with methanol and dried in air at room temperature. Yield: 0.14 g, 19%. Anal. Calcd for C$_{17}$H$_{22}$Cl$_3$Cu$_2$N$_4$O$_5$S·0.5H$_2$O ($M_r$ 636.90): C, 32.06, H, 3.64, N, 8.80, S, 5.03. Found: C, 31.95, H, 3.69, N, 8.59, S, 5.02. Solubility in water: $\geq 9.00$ mg/mL. ESI–MS (methanol), positive $m/z$ 516 [CuI(HL$_6$)Cl + Na]$^+$, 458 [CuI(HL$_6$)]$^+$. UV–vis (methanol), $\lambda_{\max}$ (ε, M$^{-1}$cm$^{-1}$): 229 (12744), 259 (16522), 299 (13967), 370 (7692) at $5.2 \times 10^{-5}$ M, 658 (438) at $1.5 \times 10^{-3}$ M. ATR–IR, cm$^{-1}$: 3304w, 3177w, 3026m, 2955w, 2924w, 1730s, 1560s, 1366s, 1294s, 1247s, 1136s, 1111s, 987s, 862s, 810m, 775m, 735m, 671m, 609m, 565vw.

Crystallographic Structure Determination. X-ray diffraction measurements were performed on Bruker X8 APEXII, Bruker D8 Venture and Oxford Diffraction SuperNova CCD diffractometers. Single crystals of H$_2$L$_1$·H$_2$L$_6$·2H$_2$O were positioned at 35, 24, 35, 24, 24 and 40 mm from the detector, and 512, 1554, 950, 687, 748 and 304 frames were measured, each for 3, 3, 3, 30, 8 and 10 s over 0.5, 0.5, 0.5, 0.5, 0.5 and 1° scan width, respectively. Single crystals of 1·CH$_3$OH, 2, 3, 4, 5 and 6·0.5CH$_3$OH were positioned at 25, 24, 25, 35, 40 and 24 mm from the detector, and 2647, 1881, 1190, 946, 748 and 1447 frames were measured, each for 24, 30, 4, 10, 60 and 60 s over 0.4, 0.5, 0.5, 0.5 and 0.4° scan width, respectively. The data were processed using SAINT software.$^{52}$ Crystal data, data collection parameters, and structure refinement details are given in Tables S2 and S3. The structures were solved by direct methods and refined by full-matrix least-squares techniques. Non-H atoms were refined with anisotropic displacement parameters. H atoms were inserted in calculated positions and refined with a riding model. The five-membered pyrrolidine ring in H$_2$L$_3$ was found to be disordered over two positions with s.o.f. 0.50:0.50, respectively. The disorder was resolved with constrained anisotropic displacement parameters using EADP instruction of SHELX-2014, respectively. Disorder with s.o.f 0.60:0.40 in one of the methoxy groups and salicylaldimine moiety was resolved with restrained bond distances and constrained displacement parameters using SADI and EADP instructions of SHELX-2014. The following software programs and computer were
used: structure solution, SHELXS-97; refinement, SHELXL-97;\textsuperscript{53} molecular diagrams, ORTEP-3;\textsuperscript{54} computer, Intel CoreDuo. CCDC 1522726–1522737.

**Powder X-ray Diffraction (XRD) Measurements.** Powder XRD was performed on a Bruker D8 diffractometer in Bragg-Brentano reflection geometry using CuK\textsubscript{α} radiation and a silicon strip 1-D detector (Lynxeye). A zero-background silicon single crystal sample holder was used. The measurements were done in a θ/2θ arrangement, with a variable slit aperture (12 mm illumination on the sample). Analysis of the obtained powder patterns was done by Rietveld refinement with the software program Topas3.

**Cell Culture.** Human cervix carcinoma cells (HeLa), lung adenocarcinoma cells (A549), colon cancer cells (LS-174) and human foetal lung fibroblast cells (MRC-5) cells were maintained as monolayer culture in the Roswell Park Memorial Institute (RPMI) 1640 nutrient medium (Sigma Chemicals Co, USA), while human myelogenous leukaemia cells (K562) were maintained in suspension culture. RPMI 1640 nutrient medium was prepared in sterile ionized water, supplemented with penicillin (192 U/mL), streptomycin (200 μg/mL), 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) (25 mM), l-glutamine (3 mM) and 10% of heat inactivated foetal calf serum (FCS) (pH 7.2). The cells were grown at 37 °C in 5% CO\textsubscript{2} and humidified air atmosphere, by twice weekly subculture.

**MTT Assay.** Cytotoxicity of the investigated copper(II) complexes 1–6 and the corresponding proligands H\textsubscript{2}L\textsubscript{1}–H\textsubscript{2}L\textsubscript{6} in comparison to cisplatin was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich) assay. The MTT colorimetric assay is based on the measurement of mitochondrial enzyme succinate dehydrogenase activity, as an indication of cell viability.\textsuperscript{55} Cells were seeded in 96-well cell culture plates (NUNC): HeLa (4000 c/w), A549 (6000 c/w), LS-174 (7000 c/w) and MRC-5 (5000 c/w) in culture medium and grown for 24 h. K562 (5000 c/w) cells were seeded 2 h before treatment. Stock solutions of investigated agents were made in DMSO at concentration of 10 mM, and further diluted with nutrient medium to desired final concentrations (in ranges up to 100 μM). Cisplatin (CDDP) stock solution was made in 0.9% NaCl at concentration of 1.66 mM and diluted with nutrient medium to desired final concentrations (in ranges up to 100 μM). The final concentration of DMSO per well did not exceed 1%. Solutions of various concentrations of examined compounds were added to the wells, except the control wells where only nutrient medium was added. All samples were prepared in triplicates. Nutrient medium

32
with corresponding agent concentrations but without target cells was used as a blank, also in triplicate.

Cells were incubated for 48 h with the test compounds at 37 °C, with 5% CO₂ in a humidified atmosphere. After incubation, 20 μL of MTT solution, 5 mg/mL in phosphate buffer solution (PBS), pH 7.2, was added to each well. Samples were incubated for 4 h at 37 °C, with 5% CO₂ in humidified atmosphere. Formazan crystals were dissolved in 100 μL 10% sodium dodecyl sulfate (SDS). Absorbance was recorded on the ThermoLabsystems 408 Multiskan EX 200–240 V after 24 h at a wavelength of 570 nm.

**Cell Cycle Analysis.** Flow cytometric analysis of cell cycle phase distribution of K562 cells treated with copper(II) complexes and cisplatin as a reference compound was performed after staining fixed cells with propidium iodide (PI). Cells were seeded at a density of 2.5 × 10⁵ cells/well in 6-well plates (Thermo Scientific Nunc™), and grown in nutrition medium. After 4 h of stabilization period, K562 cells were continually exposed to complexes 2 and 3, corresponding proligands (H₂L² and H₂L³) and cisplatin with concentrations corresponding to 1 × IC₅₀ (determined for 48 h treatment). After 24 and 48 h of continual treatment, cells were collected, washed twice with ice-cold PBS, and fixed for 30 min in 70% EtOH. After fixation, cells were washed again with PBS, and incubated with RNaseA (1 mg/mL) for 30 min at 37 °C. Cells were then stained with PI (400 μg/mL) for 15 min before flow cytometric analysis. Cell cycle phase distribution was analyzed using a fluorescence activated sorting cells (FASC) Calibur Becton-Dickinson flow cytometer and Cell Quest computer software.

**Apoptotic Assay.** Flow cytometric analysis of cell death induced by 2 and cisplatin as reference compound, was performed by Annexin V-FITC apoptosis detection kit, according to the manufacturer’s instructions (BD Biosciences Cat. No. 65874x, Pharmingen San Diego, CA, USA). K562 cells (2.5 × 10⁵) were seeded into 6-well plates (Thermo Scientific Nunc™), in 2 mL of RPMI medium. After 4 h of stabilization period, cells were treated with 2 or cisplatin with concentrations that correspond to 1 × IC₅₀ and 1.5 × IC₅₀ (determined for 48 h treatment). After treatment, cells were washed with ice-cold PBS and then resuspended in 200 μL binding buffer (10 mM HEPES/NaOH pH 7.4, 140 mM NaCl, 2.5 mM CaCl₂). 100 μL of cell suspension was transferred to a 5-mL culture tube and mixed with 5 μL of Annexin V-FITC and 5 μL of propidium iodide (PI). After incubation for 15 min, at 25 °C in the dark, 400 μL of binding buffer was added to each tube.
and analyzed using a FACS Calibur Becton-Dickinson flow cytometer and Cell Quest computer software. A minimum of 10,000 cells were analyzed per sample.

**Molecular Modeling.** The compounds were docked to the crystal structure of the R2 subunit of RNR (PDBid:1W68)(resolution 2.2 Å),\textsuperscript{14b,15} which was obtained from the Protein Data Bank (PDB).\textsuperscript{57,58} The Scigress version FJ 2.6 program\textsuperscript{59} was used to prepare the crystal structure for docking, i.e., hydrogen atoms were added, the crystallographic water molecules were removed. The software was also used to prepare the compounds for docking using MM2\textsuperscript{60} force field or by entering crystallographic co-ordinates. The docking directed at the center of the binding pocket was defined as \((x = 102.276, \, y = 87.568, \, z = 80.588)\) with 10 Å radius. One hundred runs were allowed for each compound with 100% search efficiency. The basic amino acids lysine and arginine were defined as protonated. Furthermore, aspartic and glutamic acids were assumed to be deprotonated. The GoldScore (GS),\textsuperscript{61} scoring function was implemented to validate the predicted binding modes and relative energies of the ligands using the GOLD v5.4 software suite.

**Cloning, Expression and Purification of Mouse R2.** Mouse R2 was cloned, expressed and purified based on previous protocols,\textsuperscript{62,63} with some modifications. In brief, the \(R2\) gene synthesized and cloned into a pET-3b plasmid was ordered from GenScript (GenScript USA Inc). The pET-3b-R2 plasmid was transformed into competent \(E. \, coli\) BL21 (DE3)-TIR cells (Sigma-Aldrich). Cells containing the pET-3b-R2 plasmid were grown in Terrific Broth (TB) medium containing 100 µg/mL ampicillin. Protein expression was induced by adding isopropyl \(\beta\)-D-1-thiogalactopyranoside (IPTG) to a final concentration of 0.5 mM. Cell cultures expressing the R2 protein were incubated for 12–16 h at 20 °C with vigorous shaking before harvesting. The frozen cell paste was lysed using an X-press\textsuperscript{64}, dissolved in buffer containing 100 mM Tris-HCl, pH 7.5, 10 mM EDTA, 2 mM dithiothreitol (DTT) and protease inhibitor cocktail (Roche), and cleared from nucleic acids by streptomycin sulfate (2.5%) precipitation. Mouse R2 protein was precipitated with 0.29 g/ml ammonium sulfate, dissolved in 50 mM Tris-HCl, pH 7.5, 1 mM DTT and desalted using a HiTrap Desalting column (GE Healthcare). Desalted protein was applied to a HiTrap HP Q column (GE Healthcare), and the proteins were separated with a 0 – 0.5 M KCl gradient. As a final polishing step, the protein was purified on a Superdex 200 column or a Hiload 16/60 Superdex 200 column (GE Healthcare), and stored in 50 mM HEPES, pH 7.5.
**Reconstitution of the Tyrosyl Radical in Mouse R2.** After purification, R2 protein was treated with 10 mM EDTA and 20 mM hydroxyurea, and passed through a 5 mL HiTrap desalting column (GE Healthcare) to remove iron and to quench the tyrosyl radical (Y•) before reconstitution with Fe(II). For protein sample preparations, unless stated differently, protein reactivation of apo-R2 was performed with addition of excess Fe(II) and O₂, using a solution of (NH₄)₂Fe(SO₄)₂·6H₂O, pH ~2.3, giving a 7 Fe(II)/R2 dimer ratio.

**MST Sample Preparation and Measurements.** The binding affinity of both H₂L² and complex 3 was tested against mouse R2 protein using Microscale Thermophoresis (MST). A concentrated solution of R2 protein was diluted to 500 nM R2 monomer in MST buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10 mM MgCl₂, and 0.1% pluronic (surfactant used to avoid sample adhesion to the capillaries and tubes)), and reconstituted as described above, however, with an (NH₄)₂Fe(SO₄)₂·6H₂O amount giving a 4 Fe(II)/R2 dimer ratio. Concentrated stocks of both compounds, H₂L² and 3 (3 mM in DMSO), were diluted to final concentrations of 200 µM in MST buffer containing 10% DMSO, and 1:1 serial dilutions of each compound were prepared. An equal, fixed volume of the reconstituted R2 protein in MST buffer was added to all samples, giving a final concentration of 5% DMSO and 250 nM R2 protein in each sample. The samples were left to incubate for 5 min before they were loaded into standard treated capillaries (Nanotemper Technologies). Data collection was carried out at 25 °C in a Monolith NT.Labelfree apparatus (Nanotemper Technologies). Data was recorded at 20% LED power (and 20 and 40% MST power during testing), and ran in multiple parallels. Data analysis was carried out using MO.Affinity Analysis (Nanotemper Technologies) and Origin softwares (OriginLab Corporation). As specific, ligand-induced changes in fluorescence were observed for both compounds, the changes in fluorescence intensity were directly used to determine binding affinities. The $K_D$s were determined in the Origin software (OriginLab Corporation), using a Hill Fitting model option, where the Hill slope was fixed to $n = -1$.

**EPR Sample Preparation.** Highly purified mouse R2 protein, reconstituted as described above, was used for incubation with the proligand H₂L² and complex 3. The proligand and complex are soluble in DMSO, and solutions each containing 3 mM H₂L² or 3 in DMSO were prepared. The final DMSO concentration in the protein solution was kept to 1%. Two series of samples were prepared and used for separate EPR measurements. For one EPR experiment, three samples of 180 µL 55 µM R2 monomer in 50 mM HEPES, pH 7.5, 100 mM KCl, 1% DMSO and 5% glycerol were prepared,
where two samples were also added $\text{H}_2\text{L}^2$ or 3 to final concentrations of 40 µM (yielding a molar ratio of $\sim 0.75$ tested compound/R2 monomer). For another EPR experiment, three samples of 180 µL 50 µM R2 monomer in 50 mM HEPES, pH 7.5, 100 mM KCl, 1% DMSO and 5% glycerol were prepared, where two samples were also added $\text{H}_2\text{L}^2$ or 3 to final concentrations of 50 µM (yielding a molar ratio of 1 tested compound/R2 monomer). All samples were incubated at 298 K for 1 min, transferred to quartz EPR tubes and frozen in liquid nitrogen. During the latter EPR measurements, DTT was added at two different time points (see next section).

**X-band EPR Experiments – Quenching of the Y• in the R2 protein.** X-band EPR spectra of samples containing mouse R2 protein (blank), and mouse R2 protein added either $\text{H}_2\text{L}^2$ or 3 were recorded at 30 K on a Bruker Elexsys 560 EPR spectrometer equipped with an Oxford ESR 900 helium flow cryostat, and a Super X kv319 cavity. All samples contained 5% (v/v) glycerol for vitrification during the low-temperature recordings. EPR spectra were measured at 0.05 mW microwave power and 2 G (0.2 mT) modulation amplitude, quantified by double integration of the spectra recorded under non-saturating conditions, and compared with a standard of 0.2 mM CuCl$_2$ in 1M HClO$_4$. The samples used for kinetic monitoring of the tyrosyl radical concentration were incubated at 298 K for times indicated below, and quickly re-frozen in liquid N$_2$. In the first set of EPR measurements, spectra were recorded at 30 K after incubating the samples at 298 K for 1, 16, 116, 446, and 1450 min in total. In the second set of EPR measurements, spectra were recorded at 30 K after incubating the samples at 298 K for 1, 6.5, 26, 86, 146, and 1226 min in total. In the latter measurements, 0.5 mM DTT (stock solution pH 7.5) was added after 6.5 min incubation and a second addition of 1 mM DTT (stock solution pH 6.5) was performed after 146 min of incubation at room temperature.

**UV–vis Spectroscopy of Mouse R2 with $\text{H}_2\text{L}^2$ and 3.** The active mouse R2 protein was analyzed at room temperature by UV–vis spectroscopy using an Agilent 8453 diode array ultraviolet-visible spectrophotometer. All spectra were baseline corrected. 30 µM R2 protein in 50 mM HEPES, pH 7.5, was added either $\text{H}_2\text{L}^2$ or 3 (in 1% DMSO/50 mM HEPES pH 7.5) at two different times, yielding total concentrations of compounds of 6 and 30 µM, respectively. 1 mM DTT was added twice, yielding a total DTT concentration of 2 mM.

**Associated Content**
Supporting Information
The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.inorgchem.0000000. X-ray crystallographic data (powder diffraction and single crystal), IR spectra, ^1^H and ^1^3^C NMR spectra.

Author Information

Corresponding Author
*For V.B.A.: phone, +43 1 4277 52615; E-mail, vladimir.arion@univie.ac.at.

Acknowledgments. We thank Alexander Roller for collection of X-ray data. MZ and VBA are indebted to the Austrian Science Fund (FWF) for support of this work by grant no. P28223-N34 (to V.B.A), and KKA to the Research Council of Norway for support of this work by grant no. 214239. The MST instrument was operated with the financial support of the South-Eastern Norway Regional Health Authority (grant no. 2015095; Regional Core Facility for Structural Biology).

References


40. Addison, A. W.; Rao, T. N.; Reedijk, J.; van Rijn, J.; Verschoor, G. C. Synthesis, structure and spectroscopic properties of copper(II) compounds containing nitrogen-sulphur donor ligands; the


52. SAINT-Plus, version 7.06a and APEX2; Bruker-Nonius AXS Inc.: Madison, WI, 2004.


Our findings suggest that some of the synthesized proligands and dicopper(II) complexes are effective antiproliferative agents with selectivity for cancer cells. Molecular modeling calculations, binding affinity measurements performed by microscale thermophoresis, as well as kinetic measurements of the concentration of tyrosyl radical both in the absence and in the presence of DTT by EPR and UV–vis spectroscopies indicate the formation of adducts and possible inhibition of RNR R2 by the investigated compounds.